Showing results (31-40 of 107) with videos related to
Sort By:
Pageof 11
The American Journal of Gastroenterology|February 19, 2021
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker TherapyGiulia Tosetti, Elisabetta Degasperi, Elisa Farina, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 8, 2019
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV InfectionElisabetta Degasperi, Roberta D'Ambrosio, Massimo Iavarone, et al.Journal of Hepatology|July 16, 2011
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosisGian Maria Prati, Alessio Aghemo, Maria Grazia Rumi, et al.Liver International : Official Journal of the International Association for the Study of the Liver|December 27, 2019
High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter studyMaria Elisa Mancuso, Silvia Linari, Elena Santagostino, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 6, 2016
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus InfectionAlessio Aghemo, Elisabetta Degasperi, Stella De Nicola, et al.Annals of Hematology|June 24, 2020
Liver damage and sickle cell disease: genotype relationshipMarta Bortolotti, Roberta D'Ambrosio, Mirella Fraquelli, et al.Gastroenterology|September 22, 2009
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis CMaria Grazia Rumi, Alessio Aghemo, Gian Maria Prati, et al.Plos One|February 2, 2023
Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST studyAlessio Aghemo, Marcello Persico, Roberta D'Ambrosio, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 27, 2022
Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccinationRoberta D'Ambrosio, Giuliano Rizzardini, Massimo Puoti, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 4, 2018
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosisElisabetta Degasperi, Alessio Aghemo, Stefania Paolucci, et al.Pageof 11